Jove
Visualize
Contact Us

Related Experiment Videos

Drug-induced hepatotoxicity: 2005.

Willis C Maddrey1

  • 1University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8570, USA. wcmaddrey@utsouthwestern.edu

Journal of Clinical Gastroenterology
|March 11, 2005
PubMed
Summary

Identifying drug-induced liver injury (DILI) risk before market approval is crucial. Understanding DILI mechanisms and patient susceptibility factors aids in managing risks associated with new medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final results from the ribavirin pregnancy registry, 2004-2020.

Birth defects research·2022
Same author

Changing Times in Liver Transplantation for Alcohol-Associated Liver Disease.

JAMA internal medicine·2019
Same author

Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials.

Gastroenterology·2018
Same author

The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment.

Drug safety·2017
Same author

Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.

Journal of clinical gastroenterology·2016
Same author

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.

Expert opinion on drug safety·2013
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Hepatology
  • Pharmacology
  • Toxicology

Background:

  • Market withdrawals of drugs due to liver toxicity highlight the need for better risk assessment.
  • Drug-induced liver injury (DILI) presents a broad spectrum, mimicking various liver disorders.
  • Accurate diagnosis of DILI often relies on exclusion and circumstantial evidence.

Purpose of the Study:

  • To review methods for identifying hepatic risk before drug approval.
  • To discuss the assessment of risk-benefit ratios for novel hepatotoxic agents.
  • To explore factors influencing susceptibility to DILI.

Main Methods:

  • Review of current literature on drug-induced liver injury.
  • Analysis of diagnostic challenges and characteristic signatures of DILI.
  • Examination of factors contributing to DILI, including drug metabolism and interactions.

Main Results:

  • DILI diagnosis is challenging, often requiring exclusion of other liver conditions.
  • Susceptibility to DILI is influenced by age, sex, polypharmacy, and genetic factors.
  • Metabolic activation of drugs can produce reactive intermediates leading to liver injury.

Conclusions:

  • Improved methods are needed to predict and identify hepatic risk prior to drug approval.
  • Prescriber and patient education is vital for managing risks of hepatotoxic drugs.
  • Understanding DILI mechanisms and individual susceptibility is key to mitigating liver injury.

Related Experiment Videos